Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Stock Tanks 27.2 Percent as Firms Cuts Q1 Sales Outlook in Half

NEW YORK, April 5 (GenomeWeb News) - Shares in Ciphergen were down 27.24 percent, or $.67, at $1.79 in early-afternoon trading after the company said lackluster sales will cause first-quarter revenue to fall significantly short of earlier expectations.

 

The company now expects to generate between $6.3 million and $6.7 million in revenues - or about half its receipts during the same period last year. Earlier this year,  Ciphergen projected first-quarter revenues of between $8 million and $9 million.

 

As GenomeWeb News reported this morning, the projected shortfall has prompted Ciphergen to restructure its sales program, including installing a new vice president of North American and European sales. The company also said it would boost its public relations effort.

 

"We are disappointed with our anticipated sales results for the first quarter," CEO Bill Rich said in a statement. He added that Ciphergen is "enthusiastic about the future growth of the company as we continue to address the emerging biomarker proteomics research, pharma and diagnostic markets."

 

Ciphergen said it will discuss company activities in a conference call on May 6, when it plans to release its first-quarter earnings.

 

Since Jan. 1, Ciphergen's shares have lost about 40 percent of their value, and the stock last night closed a penny above its 52-week low.

 

Ciphergen's announcement soon after a number of shareholders  called for a no-confidence vote to oust top management.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.